TrialBreast (Edinburgh, Scotland)2022

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.

Hope S Rugo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.